Dexamethasone and Zepzelca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dexamethasone (dexamethasone) and Zepzelca (lurbinectedin). Common drug interactions include hypertransaminasaemia among females and catheter site related reaction among males.

The phase IV clinical study analyzes what interactions people have when they take Dexamethasone and Zepzelca. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Dexamethasone?

Dexamethasone has active ingredients of dexamethasone. It is often used in multiple myeloma. eHealthMe is studying from 161,927 Dexamethasone users. Check the latest studies of Dexamethasone.

What is Zepzelca?

Zepzelca has active ingredients of lurbinectedin. eHealthMe is studying from 488 Zepzelca users. Check the latest studies of Zepzelca.

On Jul, 29, 2026

14 people who take Dexamethasone and Zepzelca together, and have interactions are studied.

Dexamethasone and Zepzelca drug interactions.

What are the common drug interactions of Dexamethasone and Zepzelca, by gender? *:

female:

Hypertransaminasaemia
Chest discomfort
Feeling hot
Hyperhidrosis (abnormally increased sweating)
Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Escherichia infection (bacterial infection by escherichia coli)
Anxiety
Hospitalisation
Peripheral coldness

male:

Catheter site related reaction
Death
Infusion site reaction
Injection site erythema (redness at injection site)
Injection site extravasation (flow of (blood or lymph) from injection site)
Injection site vesicles (fluid- or air-filled cavity or sac at injection site)
Peripheral swelling
Nausea (feeling of having an urge to vomit)
Phlebitis (inflammation of the walls of a vein)

What are the common drug interactions of Dexamethasone and Zepzelca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Hyperbilirubinaemia (excess of bilirubin in the blood)
Hypertransaminasaemia
Chest discomfort
Feeling hot
Hyperhidrosis (abnormally increased sweating)
Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Anxiety
Peripheral coldness

60+:

Catheter site related reaction
Death
Phlebitis (inflammation of the walls of a vein)
Pneumonia
Escherichia infection (bacterial infection by escherichia coli)
Infusion site reaction
Injection site erythema (redness at injection site)
Injection site extravasation (flow of (blood or lymph) from injection site)
Injection site vesicles (fluid- or air-filled cavity or sac at injection site)
Peripheral swelling

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 5 people, 35.71%
Pain: 4 people, 28.57%
Oedema (fluid collection in tissue): 4 people, 28.57%
Nausea And Vomiting: 4 people, 28.57%
Nausea (feeling of having an urge to vomit): 4 people, 28.57%
Small Cell Lung Cancer Metastatic (lung cancer spreads to other body parts): 3 people, 21.43%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 21.43%
Lung Cancer - Small Cell (lung cancer): 3 people, 21.43%
Gastric Ulcer (stomach ulcer): 3 people, 21.43%
Fever: 3 people, 21.43%

* Approximation only. Some reports may have incomplete information.

Do you take Dexamethasone and Zepzelca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously